CardieX Limited

As of June 30, 2024, CardieX Limited has 300.86M shares outstanding.

These figures are as of June 30, 2024. The price-to-sales ratio is 1.32, and the price-to-book ratio stands at 10.13.

These figures are as of June 30, 2024. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. CardieX Limited trades at an EV/FCF ratio of 9.89, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2024, CardieX Limited maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.50, indicating elevated leverage, while an interest coverage ratio of -6.09 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -49.77, reflecting losses generated across the asset base. Inventory turnover of 0.38 indicates how many times CardieX Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 17, 2025, CardieX Limited's stock has declined approximately 64.00% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.06.

Over the twelve months ended June 30, 2024, CardieX Limited posted a gross margin of 92.68, reflecting its pricing power and cost economics. The operating margin of -66.08 and net profit margin of -62.04 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Free cash flow yield stands at 0.82, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -52.88, meaning CardieX Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CardieX Limited's most recent stock split took place on February 18, 2022 with a 10:1 split ratio.

As of June 30, 2024, CardieX Limited has an Altman Z-Score of -9.92, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.